protein

METTL3

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about METTL3: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

383Connections

2Hypotheses

2Analyses

50Outgoing

50Incoming

0Experiments

4Debates

Summary

METTL3 is a protein involved in neurodegeneration research. Key relationships include: therapeutic target, associated with, activates. Associated with ALS, Aging, Als. Connected to 197 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	METTL3
Aliases	m6A Methyltransferase
Function	METTL3 (Methyltransferase Like 3) is the catalytic core component of the N6-methyladenosine (m6A) methyltransferase complex.
Subcellular Localization	</strong> Nucleus, cytosol</div> <div class="infobox-row"><strong>Protein Fami
Molecular Weight	64.6 kDa
Pathways	Autophagy, Akt, Pi3K, Wnt, Complement
GeneCards	METTL3
Human Protein Atlas	METTL3
Associated Diseases	Aging, Als, Alzheimer's disease, Cancer, Ftd
Known Drugs/Compounds	levodopa, metformin
Interactions	ACSL5, AKT, AMBRA1, AND, APOPTOSIS, AUTOPHAGY
SciDEX Hypotheses	RNA Modification Enzyme Modulation
KG Connections	381 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

METTL3 Protein (m6A Methyltransferase)

protein · 798 words

→

Pathway Diagram

graph TD
    METTL3["METTL3"]
    METTL3 -->|"regulates"| proteostasis["proteostasis"]
    METTL3 -->|"target for"| Neurodegeneration["Neurodegeneration"]
    METTL3 -->|"target for"| Als["Als"]
    METTL3 -->|"target for"| Aging["Aging"]
    METTL3 -->|"target for"| Ms["Ms"]
    METTL3 -->|"target for"| Cancer["Cancer"]
    METTL3 -->|"inhibits"| Carcinoma["Carcinoma"]
    ELAVL2["ELAVL2"] -->|"target for"| METTL3
    CLPP["CLPP"] -->|"target for"| METTL3
    PI3K["PI3K"] -->|"target for"| METTL3
    MTOR["MTOR"] -->|"target for"| METTL3
    BDNF["BDNF"] -->|"target for"| METTL3
    HNRNPA2B1["HNRNPA2B1"] -->|"target for"| METTL3
    GENES["GENES"] -->|"target for"| METTL3
    IGF2BP1["IGF2BP1"] -->|"target for"| METTL3
    ACSL5["ACSL5"] -->|"inhibits"| METTL3
    BAMBI["BAMBI"] -->|"inhibits"| METTL3

Outgoing (244)

Target	Relation	Type	Str
N6-Methyladenosine	regulates	compound	0.95
Parkinson'S Disease	risk_factor_for	disease	0.95
Cancer	activates	disease	0.95
m6A modification	mediates	process	0.95
m6A methylation	regulates	process	0.95
dopaminergic neurons	expressed_in	cell_type	0.90
Parkinson's Disease	risk_factor_for	disease	0.90
Substantia Nigra	expressed_in	brain_region	0.90
m6A modification	regulates	pathway	0.90
FZD10	regulates	gene	0.90
Viral Gene Expression	regulates	process	0.85
PPARGC1A	downregulates	gene	0.85
Alternative Splicing	regulates	process	0.85
m6A epitranscriptomic modification	mediates	process	0.85
ALZHEIMER'S DISEASE	modulates	disease	0.80
NEUROINFLAMMATION	modulates	process	0.80
Translation Fidelity	regulates	process	0.80
AUTOPHAGY	associated_with	process	0.80
Alzheimer's disease	implicated_in	disease	0.80
Autophagy	activates	pathway	0.80
CANCER	activates	gene	0.80
Tumor	associated_with	disease	0.75
Als	inhibits	disease	0.75
Translation Fidelity	modulates	process	0.75
proteostasis	regulates	process	0.70
m6A landscape reshaping	regulates	mechanism	0.70
Apoptosis	inhibits	pathway	0.70
RNA-protein interactions	associated_with	phenotype	0.70
RNA	regulates	gene	0.70
Inflammation	causes	disease	0.65
Cancer	therapeutic_target	disease	0.65
Als	associated_with	disease	0.65
Neurodegeneration	encodes	disease	0.65
Als	regulates	disease	0.65
Aging	associated_with	disease	0.65
Senescence	therapeutic_target	disease	0.65
Ms	regulates	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Carcinoma	inhibits	disease	0.65
Carcinoma	activates	disease	0.65
Amyotrophic Lateral Sclerosis	regulates	disease	0.65
Ftd	associated_with	disease	0.65
Traumatic Brain Injury	expressed_in	disease	0.65
Ms	inhibits	disease	0.65
Aging	encodes	disease	0.65
Neuroinflammation	expressed_in	disease	0.65
Ms	associated_with	disease	0.65
Als	encodes	disease	0.65
Ftd	therapeutic_target	disease	0.65
Als	activates	disease	0.65

Incoming (139)

Source	Relation	Type	Str
HPV E6	degrades	protein	0.95
E6	degrades	protein	0.95
E6AP	mediates	protein	0.90
β-catenin	upstream_of	protein	0.85
AUTOPHAGY	activates	gene	0.70
MTOR	associated_with	gene	0.60
HNRNPA1	activates	gene	0.60
EXOSOMES	activates	gene	0.60
STAT3	activates	gene	0.60
WTAP	associated_with	gene	0.60
SLC16A1-AS1	activates	gene	0.60
SLC16A1	activates	gene	0.60
YTHDF1	therapeutic_target	gene	0.60
TDP-43	therapeutic_target	gene	0.60
RAB11	therapeutic_target	gene	0.60
AGING	therapeutic_target	gene	0.60
MAPK	therapeutic_target	gene	0.60
IGF2BP2	regulates	gene	0.60
RNA	activates	gene	0.60
HNRNPA2B1	therapeutic_target	gene	0.60
GENES	therapeutic_target	gene	0.60
IGF2BP1	therapeutic_target	gene	0.60
AKT	associated_with	gene	0.60
ACSL5	activates	gene	0.60
BAMBI	activates	gene	0.60
AMBRA1	inhibits	gene	0.60
APOPTOSIS	inhibits	gene	0.60
FUS	associated_with	gene	0.60
C1Q	associated_with	gene	0.60
GENES	contributes_to	gene	0.60
INFLAMMATION	causes	gene	0.60
PTEN	activates	gene	0.60
STX17	therapeutic_target	gene	0.60
FUS	interacts_with	gene	0.60
ELAVL2	therapeutic_target	gene	0.60
CLPP	therapeutic_target	gene	0.60
PI3K	therapeutic_target	gene	0.60
MTOR	therapeutic_target	gene	0.60
BDNF	therapeutic_target	gene	0.60
ACSL5	inhibits	gene	0.60
BAMBI	inhibits	gene	0.60
PPARGC1A	inhibits	gene	0.60
FERROPTOSIS	activates	gene	0.60
SLC7A11	activates	gene	0.60
WNT	associated_with	gene	0.60
MAPK	associated_with	gene	0.60
HNRNPA2B1	associated_with	gene	0.60
PI3K	regulates	gene	0.60
AKT	regulates	gene	0.60
PIK3R3	regulates	gene	0.60

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
METTL3-Mediated m6A Modification of lncRNA-0021 Regulates mi	0.769	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
RNA Modification Enzyme Modulation	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (2)

Scientific analyses that reference this entity

What determines the specificity of RNA-protein interactions that drive distinct

neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.712

RNA binding protein dysregulation across ALS FTD and AD

neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.720

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (4)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning METTL3 in their description or question text

No additional research found

METTL3

Understanding Entity Pages

Summary

Wiki Pages (1)

METTL3 Protein (m6A Methyltransferase)

Pathway Diagram

Outgoing (244)

Incoming (139)

Targeting Hypotheses (2)

Mentioning Analyses (2)

What determines the specificity of RNA-protein interactions that drive distinct

RNA binding protein dysregulation across ALS FTD and AD

Experiments (0)

Related Papers (0)

Debates (4)

Debate: Liquid-to-Solid Transition Pathology Reveals Granule Weak Points

While the study identifies G3BP1 as a central node triggering phase separation,

RNA binding protein dysregulation across ALS FTD and AD

RNA binding protein dysregulation across ALS FTD and AD

Related Research